All In Biotech

Drug Trial Radar · NCT06605703

A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)

The Comparative Effectiveness of Step-down Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide: A Randomized Controlled Trial (GLP1 Transition Trial)

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 226 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

226

Actual

Start

Sep 18, 2024

Primary completion

Feb 5, 2026

Study completion Feb 5, 2026

Sponsor

Lead sponsor
WW International IncIndustry
Sponsor type
Industry
First posted
Sep 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.

Conditions

  • Obesity
  • Overweight

Interventions

  • WW ClinicBehavioral

    Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.

  • Bupropion-NaltrexoneDrug

    Bupropion-Naltrexone

  • Bupropion-Naltrexone-MetforminDrug

    Bupropion-Naltrexone-Metformin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent body weight change at 12 weeksTime frame: Baseline, 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • WW International, Inc

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.